Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Aurinia Pharmaceuticals stock

Learn how to easily invest in Aurinia Pharmaceuticals stock.

Aurinia Pharmaceuticals is a biotechnology business based in the US. Aurinia Pharmaceuticals shares (AUPH) are listed on the NASDAQ and all prices are listed in US Dollars. Aurinia Pharmaceuticals employs 300 staff and has a trailing 12-month revenue of around $129 million.

How to buy Aurinia Pharmaceuticals stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – AUPH. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Promoted for easy user experience


  • Commission-free trading
  • Commission-free crypto
  • No minimum account balance



  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.

Aurinia Pharmaceuticals stock price (NASDAQ: AUPH)

Use our graph to track the performance of AUPH stocks over time.

Aurinia Pharmaceuticals shares at a glance

Information last updated 2023-01-25.
Latest market close$9.21
52-week range$4.07 - $20.48
50-day moving average $5.68
200-day moving average $8.41
Wall St. target price$12.50
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.27

Buy Aurinia Pharmaceuticals stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs, Cryptocurrency
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Stocks, ETFs, Cryptocurrency, Alternatives
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
Winner of Finder’s Best Overall Stock Broker award.

Compare up to 4 providers

*Signup bonus information updated weekly.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Aurinia Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aurinia Pharmaceuticals price performance over time

Historical closes compared with the close of $9.21 from 2023-01-26

1 week (2023-01-20) 10.56%
1 month (2022-12-27) 124.09%
3 months (2022-10-27) 16.43%
6 months (2022-07-27) 7.34%
1 year (2022-01-27) -37.13%
2 years (2021-01-27) -42.62%
3 years (2020-01-27) 18.37
5 years (2018-01-26) 63.88%

Aurinia Pharmaceuticals financials

Revenue TTM $129 million
Gross profit TTM $-6,625,000
Return on assets TTM -17.1%
Return on equity TTM -32%
Profit margin -89.5%
Book value $2.98
Market capitalisation $1.2 billion

TTM: trailing 12 months

Aurinia Pharmaceuticals share dividends

We're not expecting Aurinia Pharmaceuticals to pay a dividend over the next 12 months.

Have Aurinia Pharmaceuticals's shares ever split?

Aurinia Pharmaceuticals's shares were split on a 1:50 basis on 22 October 2013. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aurinia Pharmaceuticals shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Aurinia Pharmaceuticals shares which in turn could have impacted Aurinia Pharmaceuticals's share price.

Aurinia Pharmaceuticals share price volatility

Over the last 12 months, Aurinia Pharmaceuticals's shares have ranged in value from as little as $4.07 up to $20.475. A popular way to gauge a stock's volatility is its "beta".

AUPH.US volatility(beta: 0.84)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aurinia Pharmaceuticals's is 0.8378. This would suggest that Aurinia Pharmaceuticals's shares are less volatile than average (for this exchange).

Aurinia Pharmaceuticals overview

Aurinia Pharmaceuticals Inc. , a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co. , Ltd. The company is headquartered in Victoria, Canada. .

Frequently asked questions

What percentage of Aurinia Pharmaceuticals is owned by insiders or institutions?
Currently 6.742% of Aurinia Pharmaceuticals shares are held by insiders and 41.937% by institutions.
How many people work for Aurinia Pharmaceuticals?
Latest data suggests 300 work at Aurinia Pharmaceuticals.
When does the fiscal year end for Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals's fiscal year ends in December.
Where is Aurinia Pharmaceuticals based?
Aurinia Pharmaceuticals's address is: 4464 Markham Street, Victoria, BC, Canada, V8Z 7X8
What is Aurinia Pharmaceuticals's ISIN number?
Aurinia Pharmaceuticals's international securities identification number is: CA05156V1022
What is Aurinia Pharmaceuticals's CUSIP number?
Aurinia Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 05156V102

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site